X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AlzeCure's ACD137 is a potent and selective negative allosteric modulator of TrkA, which is currently being evaluated for the treatment of osteoarthritis pain.
Lead Product(s): ACD137
Therapeutic Area: Musculoskeletal Product Name: ACD137
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
ACD137 is being developed within the TrkA-NAM project in AlzeCure's Painless platform. It is being evaluated in preclinical studies for the treatment of severe pain & osteoarthritis.
Lead Product(s): ACD137
Therapeutic Area: Musculoskeletal Product Name: ACD137
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. It targets severe pain in conditions such as osteoarthritis.
Lead Product(s): ACD440
Therapeutic Area: Neurology Product Name: ACD440
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain such as BDNF and NGF. EPO has granted a patent covering Alzheimer'sdisease and other disorders with cognitive impairment.
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: ACD856
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. It targets severe pain in conditions such as osteoarthritis.
Lead Product(s): ACD440
Therapeutic Area: Neurology Product Name: ACD440
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. It targets severe pain in conditions such as osteoarthritis.
Lead Product(s): ACD440
Therapeutic Area: Neurology Product Name: ACD440
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
ACD680 (alzstatin) is a gamma-secretase modulator (GSM), which constitutes a promising class of small-molecule Aβ42-lowering anti-amyloidogenic substances for preventive and disease-modifying treatment of Alzheimer's disease.
Lead Product(s): ACD680
Therapeutic Area: Neurology Product Name: ACD680
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
The presentation includes new preclinical results with AlzeCure's compound AC-0027875, which is a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin®.
Lead Product(s): AC-0027875
Therapeutic Area: Neurology Product Name: AC-0027875
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
AC-0027875 is a novel potent small molecule γ-secretase modulator and part of AlzeCure's research platform Alzstatin. γ-Secretase modulators, so called GSMs, represent a promising class of Aβ42-lowering anti-amyloidogenic compounds for treatment of Alzheimer's disease.
Lead Product(s): AC-0027875
Therapeutic Area: Neurology Product Name: AC-0027875
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
A positive modulator of both NGF/TrkA- and BDNF/TrkB-mediated signaling, ACD856 has been shown in preclinical studies to improve cognition and memory and is poised for Phase 2 clinical trials, where it is being developed primarily for the treatment of Alzheimer's disease .
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: ACD856
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
